Search

Frederick Lee Hall

from La Verne, CA
Deceased

Frederick Hall Phones & Addresses

  • La Verne, CA
  • Glendale, CA
  • 4823 Elkcreek Trl, Reno, NV 89509 (775) 853-0732
  • Honolulu, HI
  • Los Angeles, CA
  • 924 Calle Simpatico, Glendale, CA 91208

Professional Records

License Records

Frederick Hall

License #:
CPT.002952 - Expired
Issued Date:
Mar 24, 1998
Expiration Date:
Jun 30, 2011
Type:
Certified Pharmacy Technician

Lawyers & Attorneys

Frederick Hall Photo 1

Frederick Hall - Lawyer

View page
Specialties:
Personal Injury
Car Accidents
Wrongful Death
Workers Compensation
Medical Malpractice
ISLN:
1000643714
Admitted:
1982
Law School:
Mercer University - Walter F. George School of Law, JD - Juris Doctor, 1982
Frederick Hall Photo 2

Frederick Guy Hall, Los Angeles CA - Lawyer

View page
Address:
700 S Flower St #3350, Los Angeles, CA 90017
(213) 629-9500 (Office)
Licenses:
California - Active 1987
Education:
Southwestern University School of Law
University of Southern California Law School
Frederick Hall Photo 3

Frederick Hall, Glendale CA - Lawyer

View page
Address:
1253 Boynton St, Glendale, CA 91205
Phone:
(818) 551-0788 (Phone)
Experience:
54 years
Specialties:
Health Care Law
Real Estate Law
Jurisdiction:
Florida (1970)
Memberships:
Florida State Bar (1970)

Medicine Doctors

Frederick Hall Photo 4

Frederick K. Hall

View page
Specialties:
Neonatal-Perinatal Medicine
Work:
Childrens Mercy Hospital & Clinics Neonatology
2401 Gillham Rd, Kansas City, MO 64108
(816) 234-3595 (phone), (816) 302-9887 (fax)
Education:
Medical School
Michigan State University College of Osteopathic Medicine
Graduated: 1973
Procedures:
Circumcision
Conditions:
Cleft Palate and Cleft Lip
Languages:
English
Spanish
Description:
Dr. Hall graduated from the Michigan State University College of Osteopathic Medicine in 1973. He works in Kansas City, MO and specializes in Neonatal-Perinatal Medicine. Dr. Hall is affiliated with Childrens Mercy Hospital.
Frederick Hall Photo 5

Frederick D. Hall

View page
Specialties:
Ophthalmology
Work:
Azar Eye Clinic
516 Saint Landry St, Lafayette, LA 70506
(337) 235-7791 (phone), (337) 232-3937 (fax)
Education:
Medical School
Louisiana State University School of Medicine at New Orleans
Graduated: 2000
Procedures:
Ophthalmological Exam
Corneal Surgery
Destruction of Lesion of Retina and Choroid
Eyeglass Fitting
Lens and Cataract Procedures
Conditions:
Cataract
Acute Conjunctivitis
Diabetic Retinopathy
Glaucoma
Keratitis
Languages:
English
French
Description:
Dr. Hall graduated from the Louisiana State University School of Medicine at New Orleans in 2000. He works in Lafayette, LA and specializes in Ophthalmology. Dr. Hall is affiliated with Lafayette General Medical Center and Our Lady Of Lourdes Regional Medical Center.

Business Records

Name / Title
Company / Classification
Phones & Addresses
Frederick Hall
President
Xencor
Commercial Physical and Biological Research
111 W Lemon Ave Fl 3, Monrovia, CA 91016
Frederick W Hall
Administrator
Century 21 All Aces Realty
Real Estate Agents and Managers
811 N Central Avenue, Glendale, CA 91203
Frederick Hall
Chief Executive Officer President
Epeius Biotechnologies Corporation
Commercial Physical and Biological Research
111 W Lemon Ave Fl 3, Monrovia, CA 91016
Frederick Hall
President
Xencor
Commercial Physical and Biological Research
111 W Lemon Ave Fl 3, Monrovia, CA 91016
Frederick W Hall
Administrator
Century 21 All Aces Realty
Real Estate Agents and Managers
811 N Central Avenue, Glendale, CA 91203
Frederick Hall
Chief Executive Officer President
Epeius Biotechnologies Corporation
Commercial Physical and Biological Research
111 W Lemon Ave Fl 3, Monrovia, CA 91016
Frederick Hall
President
XENCOR, INC
Commercial Physical Research · Oncology · Obgyn
111 W Lemon Ave, Monrovia, CA 91016
(626) 305-5900
Frederick Hall
Administrator
Century 21 All Aces Realty
811 N Central Ave, Glendale, CA 91203
(941) 792-2111
Frederick Hall
Chief Executive Officer President
Epeius Biotechnologies Corp
Biotechnology
111 W Lemon Ave FL 3, Monrovia, CA 91016
Frederick Hall
HALL PROPERTIES INC
Frederick J Hall
Incorporator
COOPER SECURITY SERVICE, INC

Publications

Isbn (Books And Publications)

Bible Quizzes for Everybody

View page
Author

Frederick Hall

ISBN #

0801040329

Building Services Handbook

View page
Author

Frederick Hall

ISBN #

0750658479

Canadian Musical Heritage: Songs I to English Texts

View page
Author

Frederick Hall

ISBN #

0919883036

Companion to Classical Texts

View page
Author

Frederick W. Hall

ISBN #

0836968557

Dialogues of the Great Things of Brazil/

View page
Author

Frederick Holden Hall

ISBN #

0826308856

An Introduction to Abstract Algebra

View page
Author

Frederick Michael Hall

ISBN #

0521070554

An Introduction to Abstract Algebra

View page
Author

Frederick Michael Hall

ISBN #

0521084849

Musical Canada: Words and Music Honouring Helmut Kallman

View page
Author

Frederick A. Hall

ISBN #

0802057594

Wikipedia References

Frederick Hall Photo 12

Frederick William Hall

About:
Died:

1933

Work:
Position:

President

Education:

Frederick William Hall ( academic ) " Frederick William Hall " ( died 11 October 1933 ) was the President ( college ) of St John's College, Oxford from 18 December 1931 until his death in 1933.

Frederick Hall Photo 13

Frederick Hall

About:
Died:

1996

Work:
Position:

British television actor

Us Patents

Targeting Pharmaceutical Agents To Injured Tissues

View page
US Patent:
6387663, May 14, 2002
Filed:
Jul 31, 1998
Appl. No.:
09/127134
Inventors:
Frederick L. Hall - Glendale CA
Erlinda M. Gordon - Glendale CA
Vaughn A. Starnes - Pasadena CA
W. French Anderson - San Marino CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12P 2104
US Classification:
435 697, 435 691, 435 4, 435366, 435395, 435174, 435180, 4352523, 424520, 424 937, 424 94, 424 169, 530350, 530402
Abstract:
The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.

Gene Therapy Methods Using Bone Marrow-Derived Cells Expressing Blood Clotting Factors

View page
US Patent:
6410015, Jun 25, 2002
Filed:
May 11, 2000
Appl. No.:
09/569323
Inventors:
Erlinda Maria Gordon - Glendale CA
Frederick L. Hall - Glendale CA
W. French Anderson - San Marino CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A01N 6300
US Classification:
424 9321, 424 932, 435 697, 435325
Abstract:
A method for expressing a recombinant protein from bone marrow-derived cells comprises the steps of treating the bone marrow-derived cells in vitro with a TGF1 protein, which selects a population of the cells for further treatment. The selected cells can then be expanded, after which a gene encoding a therapeutic protein can be inserted into the expanded cells and thereafter express the therapeutic protein. The transduced cells can then be introduced into a mammal to produce a therapeutic result.

Mutated Cyclin G1 Protein

View page
US Patent:
6825033, Nov 30, 2004
Filed:
Feb 28, 2001
Appl. No.:
09/796149
Inventors:
Erlinda Maria Gordon - Glendale CA
Frederick L. Hall - Glendale CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12N 1585
US Classification:
4353201, 536 235
Abstract:
Methods of treating tumors, preventing restenosis, and treating hyperplasias, corneal haze, and cataracts by administering to an animal a mutated cyclin G1 protein. The mutated cyclin G1 protein may be administered to an animal by administering to an animal an expression vehicle, such as a retroviral vector comprising a gene construct encoding a mutated cyclin G1 protein.

Osteogenic Cell Growth Using A Tgfβ1-Von Willebrand's Factor Fusion Protein

View page
US Patent:
6844191, Jan 18, 2005
Filed:
Feb 15, 2002
Appl. No.:
10/076981
Inventors:
Erlinda Maria Gordon - Glendale CA, US
Frederick L. Hall - Glendale CA, US
W. French Anderson - San Marino CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12N 500
C12N 502
US Classification:
435377, 435325, 435384, 435395, 435404
Abstract:
A method for expressing a recombinant protein from bone marrow-derived cells comprises the steps of treating the bone marrow-derived cells in vitro with a TGFβ1 protein, which selects a population of the cells for further treatment. The selected cells can then be expanded, after which a gene encoding a therapeutic protein can be inserted into the expanded cells and thereafter express the therapeutic protein. The transduced cells can then be introduced into a mammal to produce a therapeutic result.

Modified Viral Surface Proteins For Binding To Extracellular Matrix Components

View page
US Patent:
6864082, Mar 8, 2005
Filed:
Jul 13, 2001
Appl. No.:
09/904923
Inventors:
Frederick L. Hall - Glendale CA, US
Erlinda Maria Gordon - Glendale CA, US
W. French Anderson - San Marino CA, US
Vaughn A. Starnes - Pasadena CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12N007/01
C12N015/63
C07H021/04
US Classification:
4352351, 4353201, 536 234, 536 231
Abstract:
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Targeting Pharmaceutical Agents To Injured Tissues

View page
US Patent:
6955898, Oct 18, 2005
Filed:
Apr 17, 2002
Appl. No.:
10/125332
Inventors:
Frederick L. Hall - Glendale CA, US
Erlinda M. Gordon - Glendale CA, US
Vaughn A. Starnes - Pasadena CA, US
W. French Anderson - San Marino CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12P021/06
US Classification:
435 691, 435 6, 4353201, 4352523, 435180, 435366, 435395, 435325, 4241921, 536 231, 530350
Abstract:
The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.

Retroviral Vectors Including Modified Envelope Escort Proteins

View page
US Patent:
7078483, Jul 18, 2006
Filed:
Aug 19, 2002
Appl. No.:
10/223599
Inventors:
Frederick L. Hall - Glendale CA, US
Erlinda Maria Gordon - Glendale CA, US
W. French Anderson - San Marino CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C07K 14/15
A61K 39/12
A61K 39/21
C12N 15/48
US Classification:
530350, 4241871, 4241991, 4242071, 530395, 4353201
Abstract:
A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein the first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and the modified retroviral envelope protein, prior to modification, includes a surface protein which includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, characterized in that the modified retroviral envelope protein has been modified such that at least 90% of the amino acid residues of the receptor binding region of the surface protein of the modified retroviral envelope protein have been removed and replaced with a non-retroviral protein or peptide.

Method Of Delivering Therapeutic Agents To Site Of Tissue Injury

View page
US Patent:
7347998, Mar 25, 2008
Filed:
Dec 15, 2004
Appl. No.:
11/014629
Inventors:
Frederick L. Hall - Glendale CA, US
Erlinda Maria Gordon - Glendale CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A01N 63/00
US Classification:
424 932, 514 44
Abstract:
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
Frederick Lee Hall from La Verne, CADeceased Get Report